Outcomes after revision of Advanced Bionics Clarion 1.2 cochlear implants.

IF 1.4 Q2 OTORHINOLARYNGOLOGY

COCHLEAR IMPLANTS INTERNATIONAL Pub Date : 2023-07-01 Epub Date: 2023-04-24 DOI:10.1080/14670100.2023.2198789

Nicholas S Andresen, Lekha V Yesantharao, Stephen P Bowditch, Deepa J Galaiya, Charles C Della Santina, Francis X Creighton, Daniel Q Sun

{"title":"Outcomes after revision of Advanced Bionics Clarion 1.2 cochlear implants.","authors":"Nicholas S Andresen, Lekha V Yesantharao, Stephen P Bowditch, Deepa J Galaiya, Charles C Della Santina, Francis X Creighton, Daniel Q Sun","doi":"10.1080/14670100.2023.2198789","DOIUrl":null,"url":null,"abstract":"Introduction: Cochlear implant reimplantation (CIR) for external processor upgrade or device failure is becoming increasingly common as the population of cochlear implant recipients ages. Patients with Advanced Bionics (AB) Clarion 1.2 cochlear implants may undergo CIR for device age/failure or desired technology upgrade so that they may use newer external processors that have improved connectivity features. The objective of this study was to evaluate audiologic outcomes for patients who were initially implanted with an AB Clarion 1.2 internal device and underwent CIR for technology upgrade or device failure.Methods: Retrospective chart review was performed at a single academic medical center for patients (pediatric and adult) with an AB Clarion 1.2 internal device who underwent CIR to a later generation AB internal device and had available audiologic data.Results: Forty-eight individuals with a Clarion 1.2 implant underwent CIR. Pre- and post-CIR speech understanding did not change for AzBio (p-value = 0.11, mean change = 12.1%, 95% CI = -2.9-27.2%), CNCw (p-value = 0.74, mean change = -1%, 95% CI = -10.4-12.4%), or HINT (p-value = 0.12, mean change = 19.9%, 95% CI = -2.6-42.4%) scores. Pure-tone averages improved following CIR (p-value < 0.01, mean change = 4.3 dB, 95% CI = 1.5-7.1 dB).Conclusions: Revision of AB Clarion 1.2 cochlear implants does not significantly worsen audiologic outcomes and may improve hearing in some individuals, but individual patient-level outcomes are variable.","PeriodicalId":53553,"journal":{"name":"COCHLEAR IMPLANTS INTERNATIONAL","volume":"24 4","pages":"190-194"},"PeriodicalIF":1.4000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10524760/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"COCHLEAR IMPLANTS INTERNATIONAL","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/14670100.2023.2198789","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/4/24 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Cochlear implant reimplantation (CIR) for external processor upgrade or device failure is becoming increasingly common as the population of cochlear implant recipients ages. Patients with Advanced Bionics (AB) Clarion 1.2 cochlear implants may undergo CIR for device age/failure or desired technology upgrade so that they may use newer external processors that have improved connectivity features. The objective of this study was to evaluate audiologic outcomes for patients who were initially implanted with an AB Clarion 1.2 internal device and underwent CIR for technology upgrade or device failure.

Methods: Retrospective chart review was performed at a single academic medical center for patients (pediatric and adult) with an AB Clarion 1.2 internal device who underwent CIR to a later generation AB internal device and had available audiologic data.

Results: Forty-eight individuals with a Clarion 1.2 implant underwent CIR. Pre- and post-CIR speech understanding did not change for AzBio (p-value = 0.11, mean change = 12.1%, 95% CI = -2.9-27.2%), CNCw (p-value = 0.74, mean change = -1%, 95% CI = -10.4-12.4%), or HINT (p-value = 0.12, mean change = 19.9%, 95% CI = -2.6-42.4%) scores. Pure-tone averages improved following CIR (p-value < 0.01, mean change = 4.3 dB, 95% CI = 1.5-7.1 dB).

Conclusions: Revision of AB Clarion 1.2 cochlear implants does not significantly worsen audiologic outcomes and may improve hearing in some individuals, but individual patient-level outcomes are variable.

查看原文本刊更多论文

Advanced Bionics Clarion 1.2人工耳蜗翻修后的结果。

引言：随着人工耳蜗接受者的年龄增长，用于外部处理器升级或设备故障的人工耳蜗再植入（CIR）越来越常见。患有Advanced Bionics（AB）Clarion 1.2耳蜗植入物的患者可能会因设备老化/故障或所需的技术升级而接受CIR，以便他们可以使用具有改进的连接功能的较新外部处理器。本研究的目的是评估最初植入AB Clarion 1.2内部设备并因技术升级或设备故障而接受CIR的患者的听力学结果。方法：在单一的学术医疗中心对使用AB Clarion 1.2内部设备的患者（儿童和成人）进行回顾性图表审查，这些患者接受了后一代AB内部设备的CIR，并有可用的听力学数据。结果：48名接受Clarion 1.2植入的患者接受了CIR。AzBio（p值=0.11，平均变化=112.1%，95%CI=-2.9-27.2%）、CNCw（p值0.74，平均变化=-1%，95%CI=-10.4-12.4%）或HINT（p值0.12，平均变化=19.9%，95%CI=-26-42.4%）评分在CIR前后的言语理解没有变化。CIR后纯音平均值有所改善（p值<0.01，平均变化=4.3dB，95%CI=1.5-7.1dB）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

COCHLEAR IMPLANTS INTERNATIONAL Medicine-Otorhinolaryngology

CiteScore

3.10

自引率

0.00%

发文量

期刊介绍： Cochlear Implants International was founded as an interdisciplinary, peer-reviewed journal in response to the growing number of publications in the field of cochlear implants. It was designed to meet a need to include scientific contributions from all the disciplines that are represented in cochlear implant teams: audiology, medicine and surgery, speech therapy and speech pathology, psychology, hearing therapy, radiology, pathology, engineering and acoustics, teaching, and communication. The aim was to found a truly interdisciplinary journal, representing the full breadth of the field of cochlear implantation.